Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Oxford researchers from the Nuffield Department of Medicine are part of a major new international initiative with the Novo Nordisk Foundation, Wellcome and the Gates Foundation to accelerate the discovery of urgently needed antibiotics. The Gram-Negative Antibiotic Discovery Innovator (Gr-ADI) brings together global expertise to tackle drug-resistant Gram-negative infections, one of the most serious threats to global health.

Research team members from left: Ed Griffen, Frank von Delft, Annette von Delft, Lizbe Koekemoer

Antimicrobial resistance (AMR) is one of the most serious global health threats, contributing to an estimated five million deaths each year and placing increasing pressure on health systems worldwide. "AMR is undermining our ability to treat even routine infections, putting millions of lives at risk, especially in lower- and middle-income countries (LMICs)," said Trevor Mundel, President of Global Health at the Gates Foundation.

Researchers from Oxford's Centre for Medicines Discovery at the Nuffield Department of Medicine are among the founding members of a new international initiative, the Gram-Negative Antibiotic Discovery Innovator (Gr-ADI), launched today by the Novo Nordisk Foundation, Wellcome, and the Gates Foundation. The consortium aims to accelerate early-stage drug discovery for Gram-negative bacterial infections, with a focus on developing direct-acting, small-molecule antibiotics targeting Enterobacteriaceae.

The Oxford team is led by Dr Annette von Delft and includes collaborators Nicole Stoesser, Lizbe Koekemoer, Paul Brennan, Frank von Delft, Phil Fowler, Thomas Lanyon-Hogg, and Ed Griffen (MedChemica). The researchers will use Oxford's internationally recognised XChem crystallographic fragment screening platform to identify novel chemical starting points against three validated Klebsiella targets.

 

Read the full story on the Nuffield Department of Medicine website.

Similar stories

Oxford spin-out raises $90 million to advance new treatments for blood cancers

Alethio Therapeutics, a University of Oxford spin-out co-founded by Professors Adam Mead (Weatherall Institute of Molecular Medicine) and Beth Psaila (Weatherall Institute of Molecular Medicine and Oxford Ludwig Institute for Cancer Research), has secured $90 million (£67 million) in oversubscribed Series A financing to develop a new generation of therapies for myeloproliferative neoplasms (MPNs)

Breakthrough in non-invasive liver testing

Two major international studies, including an imaging study led by researchers from the Radcliffe Department of Medicine, have provided new evidence on which non-invasive tests can accurately diagnose and measure the severity of metabolic dysfunction-associated steatotic liver disease (MASLD) and its more severe form, MASH, potentially reducing reliance on liver biopsy.

Researchers from the Nuffield Department of Primary Care Health Sciences contribute to parliamentary calls for overhaul of obesity care

Research from the Health Behaviors team has informed a series of parliamentary reports calling for urgent action to tackle obesity in England.

Oxford University invites 100,000 people to take part in a major study of plant-based diets

Researchers at the Nuffield Department of Population Health have launched a major new study designed to generate the most up-to-date picture of different diets in the UK, including plant-based diets, and how they affect long-term health and wellbeing.

Look beyond my skin: your psoriasis could help us understand who develops psoriatic arthritis

Adults with psoriasis across Europe are invited to take part in an online study aiming to identify who is at risk of developing psoriatic arthritis.

Professor Matthew Wood receives BioUK Special Recognition Award 2026

Professor Matthew Wood, Director and Chief Scientific Officer of the Oxford-Harrington Rare Disease Centre (OHC), has received BioUK’s Special Recognition Award 2026 for his contribution to rare disease research, therapeutic development and the wider life sciences sector.